Comorbidity profile and outcomes in patients with chronic heart failure in a Latin American country: Insights from the Colombian heart failure registry (RECOLFACA).

Autor: Campbell-Quintero S; Cardiology Department, Clínica Medilaser, Florencia, Colombia. Electronic address: sebas_campbell@hotmail.com., Echeverría LE; Cardiology Department, Fundación Cardiovascular de Colombia, Floridablanca, Colombia. Electronic address: luisedo10@gmail.com., Gómez-Mesa JE; Cardiology Department, Fundación Valle del Lili, Cali, Colombia. Electronic address: juan.gomez.me@fvl.org.co., Rivera-Toquica A; Cardiology Department, Centro Médico para el Corazón, Pereira, Colombia; Cardiology Department, Clínica los Rosales, Pereira, Colombia; Cardiology Department, Universidad Tecnológica de Pereira, Pereira, Colombia. Electronic address: alexrivera17@gmail.com., Rentería-Asprilla CA; Cardiology Department, Cardiodiagnóstico del Chocó, Quibdó, Colombia. Electronic address: carlosrentea@hotmail.com., López-Garzón NA; Cardiology Department, Hospital Universitario San José, Popayán, Colombia. Electronic address: nelsonadolfolopezg@gmail.com., Alcalá-Hernández AE; Cardiology Department, Procardio Caribe S.A.S, Barranquilla, Colombia. Electronic address: drarmandoal@yahoo.es., Accini-Mendoza JL; Internal Medicine Department, IPS centro científico asistencial S.A.S, Barranquilla, Colombia. Electronic address: joseaccini@ipscentrocientifico.com., Baquero-Lozano GA; Internal Medicine Department, Hospital Santa Clara, Bogotá, Colombia. Electronic address: garyabl@hotmail.com., Martínez-Carvajal AR; Internal Medicine Department. Hospital San Antonio de Roldanillo, Roldanillo, Colombia. Electronic address: armacamediinterna@gmail.com., Cadena A; Cardiology Department, Clínica de la Costa, Barranquilla, Colombia. Electronic address: ajcadena@clinicadelacosta.co., Zarama-Márquez MH; Internal Medicine Department, Clínica Nuestra Señora de Fátima, San Juan de Pasto, Colombia. Electronic address: mariozaramam@hotmail.com., Ramírez-Puentes EG; Cardiology Department, Sociedad Cardiológica Colombiana S.A.S, Villavicencio, Colombia. Electronic address: elkinramirez24@hotmail.com., Bustamante RI; Cardiology Department, Rafael Bustamante y Compañía Ltda, Leticia, Colombia. Electronic address: rafaignacio2000@yahoo.es., Saldarriaga C; Cardiology Department, Clínica Cardio VID, Medellín, Colombia. Electronic address: clarais@une.net.co.
Jazyk: angličtina
Zdroj: International journal of cardiology [Int J Cardiol] 2023 May 01; Vol. 378, pp. 123-129. Date of Electronic Publication: 2023 Feb 13.
DOI: 10.1016/j.ijcard.2023.02.020
Abstrakt: Background: Heart failure (HF) is usually accompanied by cardiovascular and non-cardiovascular comorbidities, which may significantly impact its prognosis. In this study we aimed to characterize the comorbidity profile and its impact in mortality in patients with HF diagnosis from the Colombian Heart Failure Registry (RECOLFACA).
Methods: RECOLFACA enrolled adult patients with HF diagnosis from 60 centers in Colombia during the period 2017-2019. The primary outcome was all-cause mortality. A Cox proportional hazards regression model was used to assess the impact of the comorbidities in mortality. A p-value of <0.05 was considered significant.
Results: From the total 2528 patients included in the registry, 2514 patients (58% males, mean age 68 years) had information regarding comorbidity diagnoses. 2321 patients (92.3%) reported at least one comorbidity. Arterial hypertension was the most frequent individual diagnosis (72%; n = 1811), followed by anemia (30.1%, n = 726). The most frequently observed coexisting comorbidities were coronary disease (CHD) with dyslipidemia, and chronic kidney disease (CKD) with type 2 Diabetes Mellitus (T2DM). Different patterns of comorbidity coexistence were observed when comparing HF patients by sex and left-ventricular ejection fraction (LVEF) classification. The only comorbidities that were significantly associated with mortality after multivariate adjustment were T2DM (HR 1.45. 95% CI 1.01-2.12), anemia (HR 1.48. 95% CI 1.02-2.16), and CHD (HR 1.59. 95% CI 1.09-2.33).
Conclusion: Multiple comorbidities were frequently observed in the patients from the RECOLFACA. T2DM, anemia and CHD were significantly associated with a higher risk of mortality, highlighting the importance of promoting an optimal follow-up and control of these conditions.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: